Importance of drug monitoring for compound sulfamethoxazole therapy in patients with Pneumocystis jiroveci pneumonia

doi:10.16138/j.1673-6087.2024.01.06

Abstract

Abstract:

Pneumocystis jiroveci pneumonia (PJP) is one of the more common and serious opportunistic infections in patients with human immunodeficiency virus (HIV). With the use of immunosuppressants and chemotherapy drugs, most PJP cases reported in China are non-HIV immunosuppressed patients. Compound sulfamethoxazole (SMZco) is the first-line drug for the treatment of PJP, and there are wide individual differences in its pharmacokinetics. Through citing a PJP case treated with SMZco under drug monitoring, a systematic review was conducted from the aspects of SMZco pharmacokinetics, dose-related adverse reactions, and optimal therapeutic dose research. It aims to demonstrate the importance of drug monitoring for sulfamethoxazole therapy, which ensures the drug reaches effective therapeutic concentrations and the occurrence of its’ adverse reactions was reduced.

Key words: Pneumocystis jiroveci pneumonia, Compound sulfamethoxazole, Therapeutic drug monitoring

CLC Number:

R563.1

FANG Jie, CHEN Chao, ZHOU Min. Importance of drug monitoring for compound sulfamethoxazole therapy in patients with Pneumocystis jiroveci pneumonia[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(01): 31-35.

Figures/Tables 3

References 24

[1]	中华医学会. 临床诊疗指南——传染病学分册[M]. 北京: 人民卫生出版社, 2006:138.
[2]	蔡柏蔷, 李龙芸. 协和呼吸病学[M]. 北京: 中国协和大学出版社, 2011:1062.
[3]	Weyant RB, Kabbani D, Doucette K, et al. Pneumocystis jirovecii: a review with a focus on prevention and treatment[J]. Expert Opin Pharmacother, 2021, 22(12):1579-1592. doi: 10.1080/14656566.2021.1915989 URL
[4]	Skalski JH, Kottom TJ, Limper AH. Pathobiology of Pneumocystis pneumonia: life cycle, cell wall and cell signal transduction[J]. FEMS Yeast Res, 2015, 15(6):fov046.
[5]	Permpalung N, Kittipibul V, Mekraksakit P, et al. A comprehensive evaluation of risk factors for Pneumocystis jirovecii pneumonia in adult solid organ transplant recipients[J]. Transplantation, 2021, 105(10):2291-2306. doi: 10.1097/TP.0000000000003576 pmid: 33323766
[6]	Braga BP, Prieto-González S, Hernández-Rodríguez J. Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases[J]. Med Clin (Barc), 2019, 152(12):502-507. doi: 10.1016/j.medcli.2019.01.010 URL
[7]	林果为, 王吉耀, 葛均波. 实用内科学[M]. 15版. 北京: 人民卫生出版社, 2017:606-609.
[8]	Liu CJ, Lee TF, Ruan SY, et al. Clinical characteristics, treatment outcomes, and prognostic factors of Pneumocystis pneumonia in non-HIV-infected patients[J]. Infect Drug Resist, 2019, 12:1457-1467. doi: 10.2147/IDR URL
[9]	Zhang Y, Ai JW, Cui P, et al. A cluster of cases of Pneumocystis pneumonia identified by shotgun metagenomics approach[J]. J Infect, 2019, 78(2):158-169. doi: S0163-4453(18)30258-5 pmid: 30149030
[10]	Permpalung N, Kittipibul V, Mekraksakit P, et al. A comprehensive evaluation of risk factors for Pneumocystis jirovecii pneumonia in adult solid organ transplant recipients[J]. Transplantation, 2021, 105(10):2291-2306. doi: 10.1097/TP.0000000000003576 pmid: 33323766
[11]	段艳, 徐媛, 杨长青, 复方磺胺甲噁唑联合卡泊芬净治疗耶氏肺孢子菌肺炎疗效与安全性的Meta分析[J]. 中国真菌学杂志, 2023, 18(1):1-7.
[12]	Stevens RC, Laizure SC, Williams CL, et al. Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects[J]. Antimicrob Agents Chemother, 1991, 35(9):1884-1890. doi: 10.1128/AAC.35.9.1884 pmid: 1952863
[13]	Blaser J, Joos B, Opravil M, et al. Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy[J]. Infection, 1993, 21(4):206-209. pmid: 8225622
[14]	Hall RG Nd, Pasipanodya JG, Meek C, et al. Fractal geometry-based decrease in trimethoprim-sulfamethoxazole concentrations in overweight and obese people[J]. CPT Pharmacometrics Syst Pharmacol, 2016, 5(12):674-681. doi: 10.1002/psp4.v5.12 URL
[15]	Varoquaux O, Lajoie D, Gobert C, et al. Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly[J]. Br J Clin Pharmacol, 1985, 20(6):575-581. doi: 10.1111/bcp.1985.20.issue-6 URL
[16]	Welling PG, Craig WA, Amidon GL, et al. Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure[J]. J Infect Dis, 1973, 128 Suppl:556-566.
[17]	Brown GR. Cotrimoxazole - optimal dosing in the critically ill[J]. Ann Intensive Care, 2014, 4:13. doi: 10.1186/2110-5820-4-13 pmid: 24910807
[18]	Haseeb A, Abourehab MAS, Almalki WA, et al. Trimethoprim-sulfamethoxazole (bactrim) dose optimization in Pneumocystis jirovecii pneumonia (PCP) management[J]. Int J Environ Res Public Health, 2022, 19(5):2833. doi: 10.3390/ijerph19052833 URL
[19]	Mori H, Kuroda Y, Imamura S, et al. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole[J]. Intern Med, 2003, 42(8):665-669. doi: 10.2169/internalmedicine.42.665 URL
[20]	Wang C, Fang W, Li Z, et al. Clinical features, risk factors, diagnosis, and treatment of trimethoprim-sulfamethoxazole-induced hypoglycemia[J]. Front Endocrinol (Lausanne), 2023, 14:1059522. doi: 10.3389/fendo.2023.1059522 URL
[21]	Wang BJ, Liu ZH, Wang QY, et al. Prolonged and recurrent hypoglycemia induced by trimethoprim-sulfamethoxazole in a Hodgkin lymphoma patient with Pneumocystis carinii pneumonia[J]. Chin Med J (Engl), 2020, 134(10):1230-1232.
[22]	Ohmura SI, Naniwa T, Tamechika SY, et al. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases[J]. J Infect Chemother, 2019, 25(4):253-261. doi: 10.1016/j.jiac.2018.11.014 URL
[23]	Kosaka M, Ushiki A, Ikuyama Y, et al. A four-center retrospective study of the efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis pneumonia in patients without HIV infection[J]. Antimicrob Agents Chemother, 2017, 61(12):e01173-e01177.
[24]	Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients[J]. J Antimicrob Chemother, 2016, 71(9):2405-2413. doi: 10.1093/jac/dkw158 pmid: 27550993

用药时间*	给药剂量	检测时间*	血钾浓度(μmol/L)	C反应蛋白(mg/L)	降钙素原(ng/mL)	C_min(μg/mL)	C_max(μg/mL)
		D1		132
		D2		142	2.04
D3~D11	0.96g/次，qid	D3	3.96	89	2.15
		D4	4.01	57	1.47
		D5	4.26	24	0.79		125
		D6	4.67	15	0.48
		D7	5.24	10
		D8	5.14	8	0.24
		D9	6.24	7	0.28		188
		D10	5.49	16	0.51
D12~D14	0.96 g/次，q12h	D12	5.01	17	0.74
D12~D14	0.96 g/次，q12h	D14	4.32	29	0.7
D15~D37	0.96 g/次，tid	D15		24	0.5		59.7
		D20	5.07
		D23	4.93	8	0.23		94.99
		D29	4.37			96.84
		D32	3.98			115.35
		D36	4.43	7	0.12	100.27
		D37		7